268.54
Krystal Biotech Inc (KRYS) 最新ニュース
Krystal Biotech Inc stock (US5012681064): Is its gene therapy pipeline strong enough to unlock new u - AD HOC NEWS
Book value per share of Krystal Biotech Inc Unsponsored BDR – BMFBOVESPA:K1YS34 - TradingView — Track All Markets
Total equity of Krystal Biotech Inc Unsponsored BDR – BMFBOVESPA:K1YS34 - TradingView — Track All Markets
Krystal Biotech (HAM:4KB) Cyclically Adjusted Price-to-FCF : (As of Apr. 11, 2026) - GuruFocus
Krystal Biotech (NASDAQ:KRYS) - intelligentinvestor.com.au
Price-Driven Insight from (KRYS) for Rule-Based Strategy - Stock Traders Daily
Krystal Biotech (HAM:4KB) Gross Property, Plant and Equipment : €161.7 Mil (As of Dec. 2025) - GuruFocus
Krystal Biotech Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Krystal Biotech Inc Phase 1/2 Clinical Trial of KB103 Final Update Call Transcript - GuruFocus
Krystal Biotech Inc (HAM:4KB) Competitors 2026 - GuruFocus
Krystal Biotech (HAM:4KB) Net Income (Continuing Operations) : €177.8 Mil (TTM As of Dec. 2025) - GuruFocus
Krystal Biotech Inc (HAM:4KB)Valuation Measures & Financial Statistics - GuruFocus
Krystal Biotech Inc (HAM:4KB) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Krystal Biotech Inc (HAM:4KB) Dividend - GuruFocus
Krystal Biotech Inc (HAM:4KB) Stock Price & 30 Year Financial Data - GuruFocus
Who's Buying or Selling Krystal Biotech Inc (HAM:4KB) Stock Today? - GuruFocus
Krystal Biotech Inc Stock Operating Data - GuruFocus
Krystal Biotech Inc (HAM:4KB) Valuation - GuruFocus
Krystal Biotech Inc (HAM:4KB) Stock News, Headlines & Updates - GuruFocus
Krystal Biotech Inc (HAM:4KB) Stock Earnings Transcripts - GuruFocus
Krystal Biotech Inc (HAM:4KB) Stock Price, Trades & News - GuruFocus
KRYS Technical Analysis | Trend, Signals & Chart Patterns | KRYSTAL BIOTECH INC (NASDAQ:KRYS) - ChartMill
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $325 - Moomoo
Layoff Watch: Can Krystal Biotech Inc weather a recession2026 PreEarnings & Fast Gain Stock Trading Tips - baoquankhu1.vn
Could This Under-the-Radar Healthcare Stock Set You Up for Life? - AOL.com
KRYS | Krystal Biotech, Inc. Common Executive Compensation - Quiver Quantitative
Krystal Biotech, Inc. ($KRYS) CEO 2025 Pay Revealed - Quiver Quantitative
KRYS PE Ratio & Valuation, Is KRYS Overvalued - Intellectia AI
Krystal Biotech, Inc. (KRYS) Stock forecasts - Yahoo Finance UK
[DEF 14A] Krystal Biotech, Inc. Definitive Proxy Statement - Stock Titan
SG Americas Securities LLC Purchases 15,591 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
3 Insider-Owned Growth Companies With Up To 81% Earnings Expansion - simplywall.st
KRYS News & Events - intellectia.ai
BSP:K1YS34 PB Ratio: 0.20 — 96% Below Median - GuruFocus
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
(KRYS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Krystal Biotech stock price forecast: consolidation likely as KRYS hovers near key support and down 2.39% - Traders Union
Assessing Krystal Biotech (KRYS) Valuation After Recent Share Price Weakness - finance.yahoo.com
Krystal Biotech (NASDAQ:KRYS) Coverage Initiated at Wolfe Research - Defense World
Krystal Biotech (BSP:K1YS34) Cyclically Adjusted PB Ratio : (As of Apr. 01, 2026) - GuruFocus
Krystal Biotech (BSP:K1YS34) EBITDA per Share : R$30.92 (TTM As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Gross Property, Plant and Equipment : R$1,033 Mil (As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Minority Interest : R$0.00 Mil (As of Dec. 2025) - GuruFocus
Q3 2024 Krystal Biotech Inc Earnings Call Transcript - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Krystal Biotech (BSP:K1YS34) Shiller PE Ratio : (As of Mar. 28, 2026) - GuruFocus
BSP:K1YS34 Pretax Margin %: 47.74% — 45% Above Median - GuruFocus
Krystal Biotech (BSP:K1YS34) Unearned Premiums - GuruFocus
BSP:K1YS34 Graham Number: R$439.15 — 14786% Above Median - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Dividend - GuruFocus
Krystal Biotech Inc FDA Approval Call Transcript - GuruFocus
Krystal Biotech (BSP:K1YS34) Cyclically Adjusted PS Ratio : (As of Mar. 28, 2026) - gurufocus.com
Krystal Biotech (BSP:K1YS34) Other Current Payables : R$-0 Mil (As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Pre-Tax Income : R$1,047 Mil (TTM As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Non Operating Income : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
Krystal Biotech (BSP:K1YS34) Net Income (Continuing Operations) : R$1,124 Mil (TTM As of Dec. 2025) - GuruFocus
BSP:K1YS34 Net Income From Continuing Operations: R$1,124 Mi - GuruFocus
Krystal Biotech Inc KB301 Phase 1 POC Efficacy Data Update Call Transcript - GuruFocus
Krystal Biotech (BSP:K1YS34) Net Income (Discontinued Opera - GuruFocus
Q4 2024 Krystal Biotech Inc Earnings Call Transcript - GuruFocus
Krystal Biotech (BSP:K1YS34) Cyclically Adjusted Price-to-F - GuruFocus
Krystal Biotech Inc Stock Intrinsic Values | BSP:K1YS34 - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Stock Price, Trades & News - GuruFocus
Q2 2024 Krystal Biotech Inc Earnings Call Transcript - GuruFocus
Krystal Biotech (BSP:K1YS34) Gross-Profit-to-Asset % : 31.50% (As of Dec. 2025) - GuruFocus
Krystal Biotech Inc (BSP:K1YS34) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Krystal Biotech Inc (BSP:K1YS34)Valuation Measures & Financial Statistics - GuruFocus
Krystal Biotech (BSP:K1YS34) Fees and Other Income - GuruFocus
大文字化:
|
ボリューム (24 時間):